Drugs / INTERFERON ALFA-2B
INTERFERON ALFA-2B
also known as
Interferon α-2b · Alfainterferona 2b Humana Recombinante · IFN · IFN α2b · Interferon-α2b (IFN) · INTRON A · Intron a hsa-free · Locteron · +2 more
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06137950 | Nov 2023 → Nov 2024 | dysplasia of cervix, human papilloma virus infection | Mongolian National University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05381363 | Jan 2022 → Jan 2023 | COVID-19 | Children's Hospital of Fudan University | Terminated | No outcome recorded |
| Phase 24 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | Met primary |
| Phase 2 | NCT02615574 | Mar 2016 → Jun 2018 | colorectal cancer | Pawel Kalinski | Withdrawn | No outcome recorded |
| Phase 2 | NCT01276730 | Oct 2007 → Aug 2015 | cervical cancer | University of Louisville | Completed | Missed primary |
| Phase 2 | NCT00548847 | Jan 2007 → Mar 2015 | leukemia | Emory University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01841775 | May 2009 → Sep 2012 | chronic hepatitis C virus infection | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06450145 | May 2024 → Dec 2025 | neoplasm | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01121731 Comparator | May 2010 → Oct 2012 | chronic hepatitis C virus infection | Digna Biotech S.L. | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INTERFERON ALFA-2B | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201558 ↗ |
| Known as | Alfainterferona 2b Humana Recombinante | “Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da...” NCT01841775 ↗ |
| Known as | IFN | “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ |
| Known as | IFN α2b | “IFN α2b” NCT05381363 ↗ |
| Known as | Interferon α-2b | “standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗8“Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy.” NCT01276730 ↗ “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574 ↗ “Interferon α2b gel treatment for 30 days.” NCT06137950 ↗ |
| Known as | Interferon-α2b (IFN) | “Interferon-α2b (IFN)” NCT02615574 ↗ |
| Known as | INTRON A | “Interferon α-2b (INTRON® A)” NCT01121731 ↗ |
| Known as | Intron a hsa-free | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201558 ↗ |
| Known as | Locteron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201558 ↗ |
| Known as | SCH 30500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201558 ↗ |
| Known as | Viraferon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201558 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1201558 ↗ |
| Route | Subcutaneous | “Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously” NCT01276730 ↗ |